$1.32
2.22%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US4277461020
Symbol
HRTX

Heron Therapeutics Inc Stock price

$1.32
-0.43 24.57% 1M
-0.92 41.07% 6M
-0.21 13.73% YTD
-0.61 31.61% 1Y
-2.75 67.57% 3Y
-12.86 90.69% 5Y
-35.80 96.44% 10Y
-134.68 99.03% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.03 2.22%
ISIN
US4277461020
Symbol
HRTX
Industry

Key metrics

Basic
Market capitalization
$202.4m
Enterprise Value
$336.9m
Net debt
$134.6m
Cash
$40.6m
Shares outstanding
153.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.4 | 1.3
EV/Sales
2.3 | 2.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-14.4%
Return on Equity
40.4%
ROCE
-0.1%
ROIC
-
Debt/Equity
-6.4
Financials (TTM | estimate)
Revenue
$149.7m | $159.6m
EBITDA
$2.4m | -
EBIT
$32.0k | $3.1m
Net Income
$-930.0k | $-2.3m
Free Cash Flow
$-29.5m
Growth (TTM | estimate)
Revenue
9.8% | 10.6%
EBITDA
105.4% | -
EBIT
100.1% | 126.6%
Net Income
98.1% | 82.8%
Free Cash Flow
-31.1%
Margin (TTM | estimate)
Gross
74.6%
EBITDA
1.6% | -
EBIT
0.0%
Net
-0.6% | -1.5%
Free Cash Flow
-19.7%
More
EPS
$0.0
FCF per Share
$-0.2
Short interest
28.2%
Employees
122
Rev per Employee
$1.2m
Show more

Is Heron Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Heron Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Heron Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Heron Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Heron Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
150 150
10% 10%
100%
- Direct Costs 38 38
19% 19%
25%
112 112
25% 25%
75%
- Selling and Administrative Expenses 98 98
4% 4%
65%
- Research and Development Expense 13 13
62% 62%
9%
2.36 2.36
105% 105%
2%
- Depreciation and Amortization 2.32 2.32
16% 16%
2%
EBIT (Operating Income) EBIT 0.03 0.03
100% 100%
0%
Net Profit -0.93 -0.93
98% 98%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Heron Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Heron Therapeutics Inc Stock News

Neutral
PRNewsWire
19 days ago
CARY, N.C. , Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights plan (the "Rights Plan") designed to protect the availability and significant potential value of the Company's net operating loss carryforwards ("NOLs") ...
Neutral
Seeking Alpha
25 days ago
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Craig Alexander Collard - CEO & Director Ira Duarte - Executive VP & CFO Mark E. Hensley - Executive VP & COO Melissa Jarel - Executive Director of Legal Conference Call Participants Brandon Richard Folkes - H.C.
Positive
The Motley Fool
26 days ago
Heron (HRTX) Q2 Acute Care Jumps 56%
More Heron Therapeutics Inc News

Company Profile

Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.

Head office United States
CEO Craig Collard
Employees 122
Founded 1983
Website www.herontx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today